Managers / Q2 2023 · view latest →
DIFESA CAPITAL MANAGEMENT, LP
CIK 0001879240 · 40 WEST 57TH STREET, SUITE# 2020, NEW YORK, NY, 10019 · 212-201-4860
Summary
Difesa Capital Management, LP reported $38M in U.S.-listed holdings across 35 positions for Q2 2023.
Its largest position, AMZN, represents 12.7% of the portfolio.
Compared with Q1 2023, the fund opened 6 new positions and exited 177.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 69.5% · $26M
- MLP · 28.2% · $11M
- Other · 2.3% · $874,890
- Equity WRT · 0.0% · $3,724
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PACBPACIFIC BIOSCIENCES CALIF IN | NEW | +36.7K | 36.7K | +$488,110 | $488,110 |
| ARLPALLIANCE RESOURCE PARTNERS L | NEW | +15.2K | 15.2K | +$281,048 | $281,048 |
| TSLATESLA INC | NEW | +975 | 975 | +$255,226 | $255,226 |
| NOGIN INC | NEW | +71.0K | 71.0K | +$83,676 | $83,676 |
| OCULOCULAR THERAPEUTIX INC | NEW | +10.0K | 10.0K | +$51,600 | $51,600 |
| CRVSCORVUS PHARMACEUTICALS INC | NEW | +10.0K | 10.0K | +$22,900 | $22,900 |
| SPYSPDR S&P 500 ETF TR | SOLD OUT | −110.0K | 0 | −$45M | $0 |
| POST HOLDINGS PARTNERING COR | SOLD OUT | −502.4K | 0 | −$5M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $0 | 1 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $0 | 1 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $38M | 35 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $153M | 212 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $129M | 244 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $196M | 237 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $178M | 253 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $198M | 254 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $147M | 225 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.